查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2046730

風濕病治療市場－全球產業規模、佔有率、趨勢、機會、預測：按適應症、通路、地區和競爭格局分類，2021-2031年

Rheumatology Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Indication, By Distribution Channel, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 182 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球類風濕性關節炎治療市場預計將從 2025 年的 496.8 億美元成長到 2031 年的 581.9 億美元，複合年成長率為 2.67%。

該市場涵蓋多種藥品，例如非類固醇消炎劑(NSAIDs)、緩解疾病類風濕性關節炎抗風濕藥 (DMARDs)、JAK 抑制劑和生物製劑，所有這些藥物均用於治療和控制類風濕性關節炎、骨關節炎和狼瘡等自體免疫和發炎性疾病。該市場的主要促進因素包括慢性自體免疫疾病在全球範圍內的日益普遍以及全球人口老化。這兩方面都推動了對有效、長期疾病管理方案的需求，以緩解症狀並維持關節功能。這些人口結構的變化必然導致對能夠緩解疼痛和減少身體殘疾的先進藥物干預措施的持續需求。根據美國風濕病學會 (ACR) 預測，到 2025 年，約有三分之一的 18 至 64 歲關節炎患者將面臨勞動能力受限的問題，凸顯了對更優治療方案的極高經濟和社會需求。然而，生物製藥和新型小分子藥物的高昂成本仍然是限制市場進一步成長的主要障礙。這種經濟障礙往往限制了患者獲得治療和開始治療的機會，尤其是在價格敏感型市場，這些市場的醫療報銷機制往往難以涵蓋慢性病治療的費用。

市場概覽
預測期 2027-2031
市場規模：2025年 496.8億美元
市場規模：2031年 581.9億美元
複合年成長率：2026-2031年 2.67%
成長最快的細分市場 醫院藥房
最大的市場 北美洲

市場促進因素

全球自體免疫疾病和風濕性疾病盛行率的不斷上升是全球類風濕關節炎治療市場的主要成長要素。隨著全球人口老化和環境風險因素的日益惡化，類風濕性關節炎和骨關節炎的發生率激增，使得持續藥物治療管理成為迫切需求。這一人口趨勢迫使醫療保健系統優先引入疾病修正治療，以維持勞動生產力並提高患者的生活品質。根據《醫學前沿》（Frontiers in Medicine）2025年4月發布的報告，全球類風濕性關節炎盛行率將達到每10萬人726.9例，凸顯了需要持續治療的患者群體不斷擴大。製藥公司大力投資開發下一代生物製藥和小分子抑制劑，推動了研發投入的大幅成長和強大的臨床管線，進一步促進了市場成長。這些巨額投資對於克服現有治療方法的局限性並推出安全性更高的標靶治療方法至關重要。例如，2025年3月，強生公司宣布將在未來四年內投資超過550億美元用於美國的研發和生產，以加速治療方法的研發，尤其是在免疫學領域。這種有利的投資環境正帶來商業性的成功，艾伯維公司於2025年10月發布的報告便印證了這一點。報告顯示，Skyrizi僅在第三季全球淨銷售額就達到了47.08億美元，年增46.8%。這充分顯示了這款創新類風濕性關節炎治療藥物的巨大市場價值。

市場挑戰

生物製藥和新型小分子藥物的高成本嚴重阻礙了全球類風濕性關節炎治療市場的成長。儘管這些先進的藥物療法在治療慢性自體免疫疾病方面展現出卓越的療效，但其高昂的價格卻成為患者獲得治療的主要障礙。為了控制這些支出，醫療保險機構和保險公司通常會採取嚴格的成本控制措施，例如階梯療法和嚴格的核准前要求。這些經濟限制導致患者無法獲得最佳治療，甚至延誤治療，阻礙了市場滲透，並降低了高品質療法的商業性覆蓋範圍，尤其是在醫療預算有限、報銷體係不完善的地區。這種經濟負擔直接阻礙了市場擴張，迫使醫療服務提供者和患者依賴價格更低廉的老藥，即使這些老藥在預防關節損傷方面可能效果較差。據關節炎基金會稱，到2025年，接受生物製藥治療類風濕性關節炎的聯邦醫療保險受益人平均每年將面臨23,544美元的費用，遠高於未接受此類治療的患者的費用。如此高昂的自付費用往往會導致治療中斷和用藥依從性差，從而降低創新藥物的收入潛力，並減緩類風濕性關節炎治療領域的整體發展勢頭。

市場趨勢

生物相似藥加速商業化正在從根本上改變全球類風濕性關節炎市場。隨著主要生物製藥的專利保護到期，醫療系統越來越重視具有成本效益的生物相似藥，以減輕治療慢性自體免疫疾病的經濟負擔。這種趨勢正在迅速改變市場佔有率，使原廠藥逐漸被生物相似藥取代，並催生出一個以價值醫療為中心的更具競爭性的市場格局。例如，2025年10月，山德士公司報告稱，其生物相似藥業務在前九個月同比成長17%，佔總銷售額的29%。這一趨勢迫使製造商調整定價策略，以在價格較低的競爭對手面前保持市場佔有率。同時，受非注射治療方法需求成長的推動，口服JAK抑制劑的處方量顯著增加。由於這些小分子藥物給藥方便，且在難治性病例中療效顯著，臨床醫生擴大選擇使用它們。因此，對靜脈注射生物製藥的依賴性正在下降。口服療法的顯著普及極大地推動了該業務板塊的收入成長。根據艾伯維截至2025年10月的會計年度財務報告，Rinvoq的全球銷售額達到21.84億美元，以報告數據計算成長了35.3%。這一趨勢表明，市場對易於使用且能提高患者用藥依從性的治療方法的需求日益成長。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：風濕病治療藥物的全球市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 適應症（僵直性脊椎炎、痛風、骨關節炎、乾癬性關節炎、類風濕性關節炎）
    • 銷售管道細分（醫院藥局、零售藥局、網路藥局）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美風濕病治療藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲風濕病治療藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區風濕病治療藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲風濕病治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲風濕病治療藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球風濕病治療市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • AbbVie Inc.
  • Amgen Inc.
  • F. Hoffmann-La Roche Ltd.
  • Pfizer Inc.
  • Johnson & Johnson Services, Inc.
  • Bristol-Myers Squibb Company
  • Novartis AG
  • UCB SA
  • Sanofi SA
  • Merck & Co., Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 16870

The Global Rheumatology Therapeutics Market is projected to expand from USD 49.68 Billion in 2025 to USD 58.19 Billion by 2031, demonstrating a compound annual growth rate (CAGR) of 2.67%. This market encompasses a broad range of pharmaceutical products, including non-steroidal anti-inflammatory drugs, disease-modifying antirheumatic drugs, JAK inhibitors, and biologics, all developed to treat and manage autoimmune and inflammatory conditions like rheumatoid arthritis, osteoarthritis, and lupus. Key drivers for this market include the increasing worldwide incidence of chronic autoimmune disorders and an aging global populace, both of which heighten the demand for effective, long-term disease management solutions to alleviate symptoms and maintain joint function. These demographic shifts inherently foster a continuous need for advanced pharmacological interventions capable of mitigating pain and reducing physical disabilities.According to the American College of Rheumatology, in 2025, approximately one-third of adults aged 18 to 64 suffering from arthritis reported limitations in their ability to work, underscoring the critical economic and social necessity for superior therapeutic alternatives. However, a significant obstacle to broader market growth remains the exorbitant cost associated with biologic therapies and novel small molecule drugs. This financial impediment frequently restricts patient access and adoption, particularly within price-sensitive markets where healthcare reimbursement frameworks often struggle to accommodate the expense of chronic treatment regimens.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 49.68 Billion
Market Size 2031USD 58.19 Billion
CAGR 2026-20312.67%
Fastest Growing SegmentHospital Pharmacies
Largest MarketNorth America

Market Driver

The rising global prevalence of autoimmune and rheumatic disorders acts as a primary stimulant for the Global Rheumatology Therapeutics Market. With an aging global population and the intensification of environmental risk factors, the incidence of conditions such as rheumatoid arthritis and osteoarthritis is escalating, creating a pressing need for consistent pharmacological management. This demographic trend compels healthcare systems to prioritize the acquisition of disease-modifying therapies to sustain workforce productivity and enhance patients' quality of life. As reported by Frontiers in Medicine in April 2025, the global prevalence rate of rheumatoid arthritis reached 726.9 cases per 100,000 population, highlighting the expanding patient pool requiring ongoing care.Market growth is further propelled by a significant increase in research and development investments and a robust clinical pipeline, as pharmaceutical companies actively fund the creation of next-generation biologics and small molecule inhibitors. These substantial financial commitments are crucial for addressing the limitations of existing therapies and introducing more targeted treatments with improved safety profiles. For instance, Johnson & Johnson announced in March 2025 a commitment of over $55 billion to manufacturing and R&D in the United States over four years, specifically to advance treatments in areas including immunology. This favorable investment climate translates into commercial success, exemplified by AbbVie's October 2025 report showing that global net revenues for Skyrizi reached $4.708 billion in the third quarter alone, marking a 46.8 percent increase and demonstrating the considerable market value of innovative rheumatology assets.

Market Challenge

The prohibitively high costs linked with biologic therapies and novel small molecule drugs represent a significant impediment to the growth of the global rheumatology therapeutics market. While these advanced pharmacological interventions demonstrate superior efficacy in managing chronic autoimmune conditions, their elevated price points create substantial barriers to patient accessibility. Healthcare systems and insurers often implement stringent cost-containment strategies, such as step therapy and rigorous prior authorization requirements, to control these expenditures. These financial limitations subsequently delay or deny patients access to optimal treatments, thereby constraining market uptake and reducing the commercial reach of premium therapeutics, especially in regions with restricted healthcare budgets or underdeveloped reimbursement frameworks.This economic burden directly hinders market expansion by forcing healthcare providers and patients to rely on older, more affordable medications, despite their potential inferiority in preventing joint damage. According to the Arthritis Foundation, Medicare beneficiaries using biologic treatments for rheumatoid arthritis in 2025 faced an average annual cost of $23,544, a figure substantially higher than costs for patients not on these regimens. Such considerable out-of-pocket expenses frequently lead to treatment abandonment or non-adherence, effectively diminishing the revenue potential of innovative drugs and stifling the overall momentum of the rheumatology therapeutics sector.

Market Trends

The accelerating commercialization of biosimilar alternatives is fundamentally reshaping the global rheumatology therapeutics market. As patent protections for key biologic drugs expire, healthcare systems are increasingly prioritizing cost-effective biosimilars to alleviate the economic burden associated with chronic autoimmune treatment. This adoption is rapidly shifting market share away from originator products, fostering a more competitive landscape centered on value-based care. For example, Sandoz reported in October 2025 that its biosimilars business grew by 17 percent at comparable rates during the first nine months of the year, accounting for 29 percent of its total net sales. This trend compels manufacturers to adjust their pricing strategies to maintain market presence against more affordable competitors.Concurrently, there is a notable rise in prescription volumes for oral JAK inhibitors, driven by a growing demand for non-injectable therapies. Clinicians are increasingly prescribing these small molecules due to their ease of administration and proven efficacy in refractory cases, which in turn reduces reliance on infusion-based biologics. This significant shift toward oral regimens is considerably boosting segment revenues. As per AbbVie's October 2025 financial results, global net revenues for Rinvoq reached $2.184 billion, marking a 35.3 percent increase on a reported basis. This trajectory underscores the increasing preference for user-friendly treatments that enhance patient adherence.

Key Market Players

  • AbbVie Inc.
  • Amgen Inc.
  • F. Hoffmann-La Roche Ltd.
  • Pfizer Inc.
  • Johnson & Johnson Services, Inc.
  • Bristol-Myers Squibb Company
  • Novartis AG
  • UCB S.A.
  • Sanofi S.A.
  • Merck & Co., Inc.

Report Scope

In this report, the Global Rheumatology Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Rheumatology Therapeutics Market, By Indication

  • Ankylosing Spondylitis
  • Gout
  • Osteoarthritis
  • Psoriatic Arthritis
  • Rheumatoid Arthritis

Rheumatology Therapeutics Market, By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Rheumatology Therapeutics Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Rheumatology Therapeutics Market.

Available Customizations:

Global Rheumatology Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Rheumatology Therapeutics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Indication (Ankylosing Spondylitis, Gout, Osteoarthritis, Psoriatic Arthritis, Rheumatoid Arthritis)
    • 5.2.2. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Rheumatology Therapeutics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Indication
    • 6.2.2. By Distribution Channel
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Rheumatology Therapeutics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Indication
        • 6.3.1.2.2. By Distribution Channel
    • 6.3.2. Canada Rheumatology Therapeutics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Indication
        • 6.3.2.2.2. By Distribution Channel
    • 6.3.3. Mexico Rheumatology Therapeutics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Indication
        • 6.3.3.2.2. By Distribution Channel

7. Europe Rheumatology Therapeutics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Indication
    • 7.2.2. By Distribution Channel
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Rheumatology Therapeutics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Indication
        • 7.3.1.2.2. By Distribution Channel
    • 7.3.2. France Rheumatology Therapeutics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Indication
        • 7.3.2.2.2. By Distribution Channel
    • 7.3.3. United Kingdom Rheumatology Therapeutics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Indication
        • 7.3.3.2.2. By Distribution Channel
    • 7.3.4. Italy Rheumatology Therapeutics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Indication
        • 7.3.4.2.2. By Distribution Channel
    • 7.3.5. Spain Rheumatology Therapeutics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Indication
        • 7.3.5.2.2. By Distribution Channel

8. Asia Pacific Rheumatology Therapeutics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Indication
    • 8.2.2. By Distribution Channel
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Rheumatology Therapeutics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Indication
        • 8.3.1.2.2. By Distribution Channel
    • 8.3.2. India Rheumatology Therapeutics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Indication
        • 8.3.2.2.2. By Distribution Channel
    • 8.3.3. Japan Rheumatology Therapeutics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Indication
        • 8.3.3.2.2. By Distribution Channel
    • 8.3.4. South Korea Rheumatology Therapeutics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Indication
        • 8.3.4.2.2. By Distribution Channel
    • 8.3.5. Australia Rheumatology Therapeutics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Indication
        • 8.3.5.2.2. By Distribution Channel

9. Middle East & Africa Rheumatology Therapeutics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Indication
    • 9.2.2. By Distribution Channel
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Rheumatology Therapeutics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Indication
        • 9.3.1.2.2. By Distribution Channel
    • 9.3.2. UAE Rheumatology Therapeutics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Indication
        • 9.3.2.2.2. By Distribution Channel
    • 9.3.3. South Africa Rheumatology Therapeutics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Indication
        • 9.3.3.2.2. By Distribution Channel

10. South America Rheumatology Therapeutics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Indication
    • 10.2.2. By Distribution Channel
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Rheumatology Therapeutics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Indication
        • 10.3.1.2.2. By Distribution Channel
    • 10.3.2. Colombia Rheumatology Therapeutics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Indication
        • 10.3.2.2.2. By Distribution Channel
    • 10.3.3. Argentina Rheumatology Therapeutics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Indication
        • 10.3.3.2.2. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Rheumatology Therapeutics Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. AbbVie Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Amgen Inc.
  • 15.3. F. Hoffmann-La Roche Ltd.
  • 15.4. Pfizer Inc.
  • 15.5. Johnson & Johnson Services, Inc.
  • 15.6. Bristol-Myers Squibb Company
  • 15.7. Novartis AG
  • 15.8. UCB S.A.
  • 15.9. Sanofi S.A.
  • 15.10. Merck & Co., Inc.

16. Strategic Recommendations

17. About Us & Disclaimer